Integra LifeSciences (NASDAQ:IART) Sets New 52-Week High – Should You Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price hit a new 52-week high on Friday . The stock traded as high as $17.83 and last traded at $17.3850, with a volume of 133133 shares. The stock had previously closed at $17.56.

Analysts Set New Price Targets

A number of equities research analysts have commented on IART shares. Truist Financial decreased their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and raised their target price for the stock from $11.00 to $16.00 in a research note on Thursday, May 28th. Argus restated a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Four research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $14.00.

Integra LifeSciences Stock Performance

The company has a market cap of $1.32 billion, a P/E ratio of -2.63, a PEG ratio of 1.18 and a beta of 1.24. The business’s 50 day simple moving average is $12.47 and its 200 day simple moving average is $11.99. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. During the same period last year, the firm posted $0.41 EPS. The company’s revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the stock. Allianz Asset Management GmbH grew its holdings in Integra LifeSciences by 88.7% during the 3rd quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company’s stock valued at $6,215,000 after buying an additional 203,834 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Integra LifeSciences during the 4th quarter valued at approximately $4,722,000. Assenagon Asset Management S.A. grew its holdings in Integra LifeSciences by 15.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock valued at $6,537,000 after buying an additional 71,950 shares in the last quarter. Tejara Capital Ltd grew its holdings in Integra LifeSciences by 42.6% during the 4th quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock valued at $2,134,000 after buying an additional 51,300 shares in the last quarter. Finally, UBS Group AG grew its holdings in Integra LifeSciences by 211.7% during the 4th quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock valued at $5,079,000 after buying an additional 277,745 shares in the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.